27.70
0.34 (1.24%)
| Previous Close | 27.36 |
| Open | 27.47 |
| Volume | 207,464 |
| Avg. Volume (3M) | 442,264 |
| Market Cap | 1,287,913,728 |
| Price / Earnings (TTM) | 12.26 |
| Price / Sales | 1.87 |
| Price / Book | 1.62 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 19.38% |
| Operating Margin (TTM) | 21.87% |
| Diluted EPS (TTM) | 2.76 |
| Quarterly Revenue Growth (YOY) | -0.80% |
| Quarterly Earnings Growth (YOY) | -41.40% |
| Total Debt/Equity (MRQ) | 86.86% |
| Current Ratio (MRQ) | 2.95 |
| Operating Cash Flow (TTM) | 193.17 M |
| Levered Free Cash Flow (TTM) | -3.71 M |
| Return on Assets (TTM) | 7.60% |
| Return on Equity (TTM) | 19.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Amphastar Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 23.68% |
| % Held by Institutions | 72.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Epoch Investment Partners, Inc. | 30 Sep 2025 | 1,133,986 |
| 52 Weeks Range | ||
| Median | 34.00 (22.74%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 07 Nov 2025 | 34.00 (22.74%) | Buy | 24.03 |
| 22 Oct 2025 | 36.00 (29.96%) | Buy | 24.52 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PRINS RICHARD K | - | 27.69 | -4,179 | -115,717 |
| Aggregate Net Quantity | -4,179 | |||
| Aggregate Net Value ($) | -115,717 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 27.69 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PRINS RICHARD K | Director | 25 Nov 2025 | Sell (-) | 4,179 | 27.69 | 115,717 |
| PRINS RICHARD K | Director | 25 Nov 2025 | Option execute | 4,179 | - | - |
| Date | Type | Details |
|---|---|---|
| 24 Nov 2025 | Announcement | Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference |
| 12 Nov 2025 | Announcement | Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference |
| 06 Nov 2025 | Announcement | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025 |
| 27 Oct 2025 | Announcement | Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |